ATXI News and Press, Avenue Therapeutics Inc. From 04/29/24

2024-04-29 08:17:37 ET More on pre-market losers & stocks. Deutsche Bank AG (DB) Q1 2024 Earnings Call Transcript Deutsche Bank May Knock Q1 Estimates Out Of The Park Buy Altimmune's Potential Market Disruption With Pemvidutide Deutsche Bank reports 10%Y/...

MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 20.6% to $0.0626 on volume of 316,091,551 shares Snap Inc. Class A (SNAP) rose 27.6% to $14.55 on volume of 158,621,648 shares PROSHARES TRUST (SQQQ) fell 4.8% to $11.43 on volume of 135,432,504 share...

2024-04-25 09:02:03 ET Avenue Therapeutics Inc (ATXI) announced stock split at a ratio of 1-for-75 on 2024-04-26 ... Full story available on KlickAnalytics.com

A look at the top 10 most actives in the United States Chicken Soup for the Soul Entertainment Inc. (CSSE) rose 179.3% to $0.4253 on volume of 213,352,319 shares Tesla Inc. (TSLA) rose 12.1% to $162.13 on volume of 179,967,315 shares PROSHARES TRUST (SQQQ) fell 0.8% to $11.81 on volume of...

A look at the top 10 most actives in the United States Chicken Soup for the Soul Entertainment Inc. (CSSE) rose 43.1% to $0.218 on volume of 39,190,339 shares Amesite Inc. (AMST) rose 100.0% to $4.0001 on volume of 36,290,765 shares Tesla Inc. (TSLA) rose 10.7% to $160.21 on volume of 32,...

2024-04-24 07:58:30 ET More on Avenue Therapeutics Avenue Therapeutics granted extension for Nasdaq compliance Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical earnings data for Avenue Therapeutics Financial information for Avenue Therape...

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

2024-03-19 06:53:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avenue Therapeutics (NASDAQ: ATXI ) just reported results for the fourth quarter of 2023. Avenue Therapeutics reported earnings per share of 56 cents. This was above the a...